Who
Coelho Rogerio Vivaldi
Director
Company insider
Files Form 4 as: Director, Crinetics Pharmaceuticals; Director, Viatris; President and CEO, Sigilon Therapeutics; EVP, Chief Global Therapeutics, Bioverativ; Chief Commercial Officer, Spark Therapeutics; President and CEO, Minerva Neurosciences.
In numbers
- Trades disclosed
- 109
- Buys
- 3
- Sells
- 7
- Bought
- $418K
- Sold
- $4.4M
- Companies
- 6
- Companies where not an officer
- 2
- First trade
- 30 Jun 2014
- Last trade
- 1 Sep 2026
- Last filed
- 1 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $1.1M13,300 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $504K5,925 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $2.0M35,000 at $56.69 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $2.0M35,000 at $56.69 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $584K8,750 at $66.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $584K8,750 at $66.71 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $1.1M17,500 at $64.68 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $504K12,500 at $40.29 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $545K10,350 at $52.67 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | $478K9,730 at $49.13 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $1.1M13,300 at $85.00 | filing |
| 1 Sep 2026filed 1 Sep 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code D | $504K5,925 at $85.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $120K3,000 at $40.00 | filing |
| 2 Jul 2026filed 7 Jul 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $120K3,000 at $40.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | Crinetics PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —5,925 at $0.00 | filing |
| 18 Jun 2026filed 22 Jun 2026 | Crinetics Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,730 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.